Presentation is loading. Please wait.

Presentation is loading. Please wait.

Supplementary Table 1: Clinicopathologic characteristics of 100 patients with invasive breast cancer Clinical characteristicsNumber of cases (%) Median.

Published byBonnie Hudson Modified over 8 years ago

Similar presentations

Presentation on theme: "Supplementary Table 1: Clinicopathologic characteristics of 100 patients with invasive breast cancer Clinical characteristicsNumber of cases (%) Median."— Presentation transcript:

1 Supplementary Table 1: Clinicopathologic characteristics of 100 patients with invasive breast cancer Clinical characteristicsNumber of cases (%) Median age (years)56 (26-86) Tumor category T149 T237 T314 Chemotherapy, no (%) Yes55 No45 Radiation Therapy, no (%) Yes56 No44 Stage, no (%) I45 II44 III11 ER status, no (%) Positive56 Negative44 PR status, no (%) Positive55 Negative45 HER-2 status, no (%) Positive33 Negative67 TNBC, no (%) Positive27 Negative73

2 Supplementary Table 2: Interacting proteins of LMW-E(T1) identified from RePCA screen

3 Supplementary Table 3: Doubling time (hrs.) of 76NE6 TDCs+KD ACLY Scr.shRNAshACLY #1shACLY #2 Parental22.9832.2733.45 EL19.9220.3620.71 T125.6139.3838.03 2.215.2823.2917.98 3.122.2725.4826.75 4.223.2817.3920.12

4 Supplementary Table 4: ACLY inhibition delays tumor formation Cyclin E Expression shRNA sequence # of tumors 3 weeks # of tumors 12 weeks Vector Scr.shRNA100% (5/5) shACLY #1100% (5/5) shACLY#2100% (5/5) EL Scr.shRNA100% (5/5) shACLY #1100% (5/5) shACLY#2100% (5/5) LMW-E(T1) Scr.shRNA100% (5/5) shACLY #180% (4/5)100% (5/5) shACLY#240% (2/5) LMW-E(T2) Scr.shRNA100% (5/5) shACLY #10% (0/5)100% (5/5) shACLY#220% (1/5)40% (2/5)

5 ConditionIntensityPercentage (%) Adipophilin H-score* Ki-67 (%) (Mean) SEMLMWE Vector Scr123 31.1671.740positive Vector shACLY#1 112 43.51.607negative Vector shACLY#2 213 572.291negative EL Scr224 23.8331.814positive EL shACLY#1 112 40.8332.048negative EL shACLY#2 123 54.6671.167positive T1 Scr235 281.258positive T1 shACLY#1 000 23.1670.601negative T2 shACLY#2 123 300.764negative T2 Scr336 36.1671.093positive T2 shACLY#1 213 36.6671.202negative T2 shACLY#2 112 25.3331.014negative Supplementary Table 5: Adipophilin, Ki-67 and LMW-E immuno- expression in xenograft tumors *H score: Summary of intensity and percentage score; 0-3: low; 4-7 high

6 Supplementary Table 6 : Adipophilin scoring system ScoreIntensityPercentage 0negative0 1weakly positive<5% 2moderately positive6-25% 3strong positive26-75% 4strong positive>75%

Download ppt "Supplementary Table 1: Clinicopathologic characteristics of 100 patients with invasive breast cancer Clinical characteristicsNumber of cases (%) Median."

Similar presentations

Oncotype DX® Breast Cancer Assay Clinical Data Review

Oncotype DX® Breast Cancer Assay Clinical Data Review
Xeloda X-panding options in the adjuvant treatment of breast cancer

Xeloda X-panding options in the adjuvant treatment of breast cancer
516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.

516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.
Triple-Negative Breast Cancer

Triple-Negative Breast Cancer
Comparison of Mutations and Protein Expression in Potentially Actionable Targets in 5500 Triple Negative vs. non-Triple Negative Breast Cancers Joyce A.

Comparison of Mutations and Protein Expression in Potentially Actionable Targets in 5500 Triple Negative vs. non-Triple Negative Breast Cancers Joyce A.
Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.

Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.
Statistical Issues in Incorporating and Testing Biomarkers in Phase III Clinical Trials FDA/Industry Workshop; September 29, 2006 Daniel Sargent, PhD Sumithra.

Statistical Issues in Incorporating and Testing Biomarkers in Phase III Clinical Trials FDA/Industry Workshop; September 29, 2006 Daniel Sargent, PhD Sumithra.
Giuliano Pre-SSO mins ASCO Z mins

Giuliano Pre-SSO mins ASCO Z mins
Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.

Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.
Legends for supplementary figures Fig s1. A: Western blot showing the suppression of SRp20 expression by Dox induction of SRp20 siRNAs in SKOV3 sublines.

Legends for supplementary figures Fig s1. A: Western blot showing the suppression of SRp20 expression by Dox induction of SRp20 siRNAs in SKOV3 sublines.
Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.

Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.
TATFACFAC Combined NEO pCRRDTotalpCRRDTotalpCRRDTotalpCRRDTotal ER+302482781719721413758960521581 ER-631241874992141226385134279413 Total933724656628935535139174194800994.

TATFACFAC Combined NEO pCRRDTotalpCRRDTotalpCRRDTotalpCRRDTotal ER ER Total
BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.

BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.
What is Cancer? How it occurs and cell cycle regulation.

What is Cancer? How it occurs and cell cycle regulation.
The All Breast Cancer Report was published in October 2009 breastscreen/research.html#breast- cancer-report.

The All Breast Cancer Report was published in October breastscreen/research.html#breast- cancer-report.
Supplementary Figure 1. Supplementary Figure 2 All patients CharacteristicN% Median Age of patients 58 yrs ER Positive 40 69 Negative 18 31 PR Positive.

Supplementary Figure 1. Supplementary Figure 2 All patients CharacteristicN% Median Age of patients 58 yrs ER Positive Negative PR Positive.
Racial/Ethnic Disparities in Cancer Incidence, Survival and Treatment Linda C. Harlan, PhD, MPH National Cancer Institute Division of Cancer Control and.

Racial/Ethnic Disparities in Cancer Incidence, Survival and Treatment Linda C. Harlan, PhD, MPH National Cancer Institute Division of Cancer Control and.
Supplementary Figures: Fig. 1, 2, and 3 show H1299 cells overexpressing Set7/9wt or H297A catalytic mutant and U2-OS, U2-OS Set7/9KD, and U2-OS Set7/9.

Supplementary Figures: Fig. 1, 2, and 3 show H1299 cells overexpressing Set7/9wt or H297A catalytic mutant and U2-OS, U2-OS Set7/9KD, and U2-OS Set7/9.
New York University Department of Radiation Oncology A Phase I-II Study of Adjuvant Concurrent Carboplatin and Accelerated Radiotherapy for Triple Negative.

New York University Department of Radiation Oncology A Phase I-II Study of Adjuvant Concurrent Carboplatin and Accelerated Radiotherapy for Triple Negative.
Introduction MarkerPolymorphisms in CYP2C19 (*2 and *17) assessed by Taqman allelic discrimination ObjectivesTo evaluate the predictive capacity of CYP2C19.

Introduction MarkerPolymorphisms in CYP2C19 (*2 and *17) assessed by Taqman allelic discrimination ObjectivesTo evaluate the predictive capacity of CYP2C19.

Similar presentations

Ads by Google